Jooryung Huh

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Blood · 2013 · 679 citations · Full text

Medicine, Cancer Biology, Oncology +15

Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study

Jeeyun Lee, Cheolwon Suh, Young Hyeh Ko et al. · Journal of Clinical Oncology · 2005 · 614 citations · Full text

Medicine, Oncology, Cancer Immunology +12

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Zijun Y. Xu‐Monette, Lin Wu, Carlo Visco et al. · Blood · 2012 · 391 citations · Full text

Medicine, Hematology, Oncology +14

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Shimin Hu, Zijun Y. Xu‐Monette, Aarthi Balasubramanyam et al. · Blood · 2013 · 246 citations · Full text

Medicine, Hematology, Oncology +14

Frequent detection of <scp><i>BRAF</i>^V</scp>^600E mutations in histiocytic and dendritic cell neoplasms

Heounjeong Go, Yoon Kyung Jeon, Jooryung Huh et al. · Histopathology · 2014 · 229 citations

Medicine, Oncology, Pathology +15